Taken together, these data suggest that cancer cells with minimal reserve mitochondria capacity, or tumours which are dependent on OXPHOS for survival and growth, are more sensitive to eIF5A inhibition and that devising therapeutic interventions that target this protein could provide a viable therapeutic option. This evidence concerns the gene EIF5A and cancer.